source
- FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a rec…
- FDA orders label warnings for GLP-1 drugs over rare eye-loss riskThe U.S. Food and Drug Administration has issued a safety communication that requires all glucagon-like peptide-1 receptor agonist (GLP-1 RA) products to add new warnings to their labeling. The ad…